Trending...
- Maryland: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Third Anne Arundel County Backyard Flock in 2025 - 111
- Where the Miami Dolphins Stand After Week 1
- DivX Unveils New Educational Blog Series to Simplify MKV to MP4 Video Conversion
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the Jefferies 2022 Healthcare Conference, on June 8th, in New York, NY.
Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analyst Roger Song, M.D. will host a fireside chat with Mr. Semerjian. An archived recording of the chat will be available for thirty days on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations, beginning Wednesday, June 8 at approximately 3:30 p.m. ET.
More on Marylandian
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company's science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Contacts
Investor and Media Contact:
Brian Hahn
(301) 417-4254
bhahn@glycomimetics.com
Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Research Analyst Roger Song, M.D. will host a fireside chat with Mr. Semerjian. An archived recording of the chat will be available for thirty days on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations, beginning Wednesday, June 8 at approximately 3:30 p.m. ET.
More on Marylandian
- AZETHIO Crypto Exchange Whitepaper Reveals MPC-Secured Infrastructure Processing 1.2 Million Transactions Per Second
- CELOXFI Platform Demonstrates Advanced Security Architecture and Regulatory Framework
- Work 365 Launches PV 3.0: The Keystone Power App for Microsoft CSPs
- Local consultant shows small businesses how to turn red tape into real money
- SYZMIK Partners with Green Bay Packers to Provide X7C Headbands to Wisconsin Girls Flag Program
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company's science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is located in Rockville, Maryland in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Contacts
Investor and Media Contact:
Brian Hahn
(301) 417-4254
bhahn@glycomimetics.com
Filed Under: Business
0 Comments
Latest on Marylandian
- Teaming Agreement with Emtel Energy USA to Advance Thin-Film PV Energy Storage Capabilities; NASA agreements for Solar Space Tech; Ascent Solar $ASTI
- Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
- Precision Antibody to Attend the World Clinical Biomarkers & CDx Summit 2025 in Boston
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
- Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
- Cryptocurrency Quarterly Trading Volume Surpasses $15 Trillion Record High as BrazilNex Acknowledges Industry 'Growing Pains' Amid Market Speculation
- AHRFD Initiates Legal Proceedings Against Anwalt.de for Publishing Defamatory and False Content
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
- Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
- Meet Donna L. Quesinberry: Angelic Realms and Transcendent Verse
- How DonnaInk Elevates Indie Authors with Editorial Precision
- NEW power supply release from Kepco Dynatronix - HSP Advanced
- St. Augustine Honors Hispanic Heritage Month
- Vesica Health Receives AUA Guideline Inclusion
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- Maryland: Poultry Farmers Urged to Practice Enhanced Biosecurity
- 10xLaw.com Extends Employment Opportunity to Kim Kardashian
- DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies